Squarepoint’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Squarepoint’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,647	Closed	-$269K	–	2999
2020 Q2	$269K	Buy	+5,647	New	+$263K	﹤0.01%	1672
2020 Q1	–	Sell	-7,425	Closed	-$426K	–	2794
2019 Q4	$426K	Sell	7,425 -11,430	-61%	-$566K	﹤0.01%	1858
2019 Q3	$678K	Buy	+18,855	New	+$736K	0.01%	1456

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Squarepoint's EIDX Position: Q3 2020 in Review

Squarepoint sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2020, closing a stake of 5,647 shares — an estimated $269K sold.

Squarepoint first reported a position in EIDX in Q3 2019 and held it in 3 quarters. The position peaked at $678K in Q3 2019. 91 funds tracked by Wall St. Rank hold EIDX as of Q3 2020.

Squarepoint reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Squarepoint sold 5,647 Eidos Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $269K.
Squarepoint first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 3 quarters.
Squarepoint's Eidos Therapeutics, Inc. Common Stock position peaked at $678K in Q3 2019.
91 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Squarepoint's 13F filing for Q3 2020, filed 16 Nov 2020.